<DOC>
	<DOCNO>NCT02114333</DOCNO>
	<brief_summary>This study compare two vaccine develop prevent and/or lessen effect shingle . One vaccine live ( Zostavax , license FDA ) , herpes zoster subunit ( HZ/su ) , contain piece shingle virus ( live ) ingredient may enhance body 's immune response vaccine , currently investigational . The vaccine compare assess ability stimulate protection shingle . The study provide opportunity determine safety profile vaccine single trial . The study also look effect age immune response two vaccine persistence response .</brief_summary>
	<brief_title>Comparison Live Herpes Zoster Vaccine Recombinant Vaccine 50-59 70-85 Year Olds</brief_title>
	<detailed_description>160 people Denver area participate . Duration 5 year 10-12 visit period . Subjects randomize one 4 arm receive either Zostavax HZ/su . In single blind study subject receive 2 injection : one first visit ( Day 0 ) second Day 60 . HZ/su subject receive vaccine visit ; Zostavax subject receive vaccine first visit placebo Day 60 visit . Blood collect subject visit . Some subject spit tube saliva collection . A urine sample collect prior vaccination subject woman childbearing potential . Subjects ask complete diary record reaction 30 day injection . The Day 90 visit last one annual visit blood draw begin Day 365 . Some subject also see Year 2 Year 4 ; subject see Year 5 blood draw .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>History varicella residence int US 30 year For Arms C D prior live zoster vaccine least 5 year previously For Arms A B Age 5059 7085 For Arms C D Age 7085 For woman childbearing potential , negative pregnancy test agreement use adequate contraception 30 day 3 month last dose study vaccine History herpes zoster For Arms A B prior live zoster vaccine Immune compromise illness therapy chronic illness Allergy previous herpes zoster vaccine Other investigational drug vaccine within past 6 month study last visit Blood product 3 month prior plan study Concomitant nontopical antiviral therapy within 3 day prior 7 day vaccination . Vaccines within 2 week ( inactive vaccine ) 4 week ( live vaccine ) prior study 30 day dose either vaccine . Pregnancy breastfeed Current drug addiction alcoholism .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Shingles vaccine</keyword>
	<keyword>Immune response</keyword>
	<keyword>Zoster vaccine</keyword>
</DOC>